Cerenome Q2 2026: $9.0M Net Loss, Going Concern Doubt, Cash Down to $2.4M
CNSY sits 21% above its 52-week low of $2.9.
Summary
Cerenome reported a $9.0M Q2 net loss, disclosed going concern doubt, and showed cash and investments of $8.6M. The company is under Nasdaq monitoring through August 22, 2026 and continues to rely on dilutive financing.
Key Events · Earnings and Guidance · CNSY
-
Q2 Net Loss of $9.0M
Net loss of $9.0 million for Q2 2026, compared to net income of $5.2 million in Q2 2025. Revenue was only $0.4 million in grant revenue, down from $1.4 million a year ago.
-
Going Concern Doubt
Management states substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need to raise additional capital.
-
Cash and Investments at $8.6M
Cash and cash equivalents of $2.4 million plus investments of $6.2 million as of June 30, 2026, down from $8.8 million at December 31, 2025.
-
Nasdaq Monitoring Through Aug 22
Company is currently compliant with Nasdaq's Minimum Stockholders' Equity Requirement but subject to monitoring through August 22, 2026. Failure to maintain compliance could lead to delisting.
Analysis · CNSY · Industrial Applications And Services
Cerenome's Q2 2026 10-Q reveals a $9.0 million net loss on just $0.4 million in grant revenue, with cash and investments falling to $8.6 million from $8.8 million at year-end. The company explicitly states substantial doubt about its ability to continue as a going concern, and it remains under Nasdaq monitoring for the Minimum Stockholders' Equity Requirement through August 22, 2026. The filing details heavy reliance on dilutive financing: a $15.0 million January 2026 public offering, $1.8 million from an at-the-market program, and a $4.5 million payment to settle investor liabilities. Operating expenses more than tripled year-over-year, driven by clinical trial costs and CNSide commercialization. The company's survival hinges on raising additional capital, with no assurance it can do so.
At the time of this filing, CNSY was trading at $3.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $2.90 to $23.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.